生物传感器技术公司Profusa Inc宣布，其Lumee™组织氧监测系统已获得首批采购订单。基于市场对该创新产品的强劲需求，公司同步调升了2026财年的营收预期。
此次订单标志着可植入式生物传感器技术商业化的重要里程碑。Lumee™系统通过实时监测组织氧水平，为慢性病管理和术后康复提供精准数据支持。
公司首席执行官表示，订单量超出初期预期，反映出医疗市场对无创监测解决方案的迫切需求。此次营收指引的上调幅度达15%，主要源于欧洲和北美医疗机构采购计划的加速落地。
随着全球人口老龄化进程加剧，慢性疾病监测市场正呈现爆发式增长。Profusa的技术平台通过微型传感器与智能手机的无缝连接，有望重塑家庭健康管理生态。分析师指出，该订单可能成为公司抢占百亿美元级医疗监测市场的关键转折点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.